Clinical value of induction therapy with preoperative single-bolus high-dose ATG in sensitive renal transplant recipients
- VernacularTitle:致敏肾移植受者术前单次大剂量抗胸腺细胞球蛋白诱导治疗的价值
- Author:
Shunliang YANG
;
Jianming TAN
;
Weizhen WU
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Panel reactive antibody;
Rejection;
Immunosuppression;
Anti-thymocyte globulin
- From:
Chinese Journal of Urology
2001;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
0.05).The graft function of high dose group returned to normal within 3 to 7 days after operation.Delayed recovery of graft function occurred in 2 cases of routine dose group;in 1 case it returned to normal on the 21st day after operation, in the other the serum creatinine level fell down to 300 ?mol/L on the 45th day.There was no severe adverse event such as fever,chill,headache,heart-throb,dyspnea during ATG intravenous perfusion.And no serious infection occurred in the 2 groups during the first 3 months postoperatively.Hepatic function damage occurred in 1 case of high dose group.Follow-up ranged from 4 to 14 months.All recipients of high dose group survived with good graft function;5 of them could do housework. Only one graft lost its function in routine dose group. Conclusions On the basis of optimal selection of the donor and recipient,preoperative single-bolus high-dose ATG is effective and safe for the sensitive recipients as immune induction therapy, which may become one of the new induction treatments before transplantation.
